Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loratadine Clinical Trials On General Hives Suggested By NDAC Members

This article was originally published in The Tan Sheet

Executive Summary

An OTC switch of Schering-Plough's non-sedating antihistamine Claritin for general hives would require data from an evidence-based study of acute urticaria, Jesse Joad, MD, UC-Davis Medical Center, asserted at a meeting of FDA's Nonprescription Drugs Advisory Committee April 22

You may also be interested in...



Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports

Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said

Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports

Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said

Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval

Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy

Related Content

Topics

UsernamePublicRestriction

Register

PS093945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel